Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISTAS study of volixibat for pruritus in primary sclerosing cholangitis
NL-OMON59577Phase 2Active, not recruiting
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of volixibat in Primary Sclerosing Cholangitis (PSC), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoint: Mean change in Adult ItchRO score. Started Jun 2024; status: active, not recruiting.
02
Drugs
volixibat
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NL-OMON59577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59577.